Showing 696 results
-
Media Release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of…
-
Media Release /
-
Media Release /- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are…
-
Media Release /
-
Media Release /Three leading US cardiology societies have jointly issued a clinical practice guideline update that has redefined standard of care treatment for heart failure and given Entresto® a strong Class I…
-
Media Release /
-
Media Release /Novartis has established FortiHFy, the largest global clinical program in the heart failure disease area, comprising over 40 active or planned clinical studies designed to generate an array of…
-
Media Release /
-
Media Release /-- Subject to approvals, Ilaris® (canakinumab) will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF-- Designations support…
-
Media Release /
